Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial

Yung‐Jue Bang(Seoul National University), Narikazu Boku(Tokyo Medical University), Shukui Qin(81th Hospital of PLA), Se Hoon Park(Samsung Medical Center), Seock‐Ah Im(Seoul National University), Xiaojin Shi, Philip Rowe(University of Strathclyde), Keun‐Wook Lee(Seoul National University Bundang Hospital), Darren Hodgson(AstraZeneca (United Kingdom)), Lin Shen(Hangzhou Normal University), Rui‐Hua Xu(Sun Yat-sen University), Keisho Chìn(The Cancer Institute Hospital), Yu-Zhen Liu(AstraZeneca (United Kingdom)), Gershon Y. Locker(AstraZeneca (United States)), Nong Xu(First Affiliated Hospital Zhejiang University), Sun Young Rha(Yonsei University)
The Lancet Oncology
November 3, 2017
10.1016/s1470-2045(17)30682-4
Cited by 291

Related Papers

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
|The Lancet|2010|7.3k
Palbociclib and Letrozole in Advanced Breast Cancer
|New England Journal of Medicine|2016|2.9k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer
|International Journal of Clinical Oncology|2017|2.5k
Maintenance Olaparib for Germline <i>BRCA</i> -Mutated Metastatic Pancreatic Cancer
|New England Journal of Medicine|2019|2.2k